deucravacitinib

all catalysts(0)

nothing on the calendar yet

News(8)

• MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
  MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
  fiercebiotech · 1d ago
• InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
  InnoCare Pharma announced Monday that its oral tyrosine kinase 2 (TYK2) inhibitor fadeucravacitinib met the primary endpoint in a phase 3 trial of adults with moderate-to-severe plaque psoriasis.
  fiercebiotech · 15d ago
• Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update
  Takeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to clear or almost clear scalp psoriasis in 75% of patients.
  fiercebiotech · 26d ago
• Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial
  A phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.
  fiercebiotech · 26d ago
• 10 clinical trials to watch in the second half of 2026
  The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
  biopharma_dive · 1mo ago
• Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
  Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. Zasocitinib induce…
  endpoints · 2mo ago
• Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
  The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
  biopharma_dive · 2mo ago
• Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
  Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
  biopharma_dive · 3mo ago